Biovica International AB (publ)
Save
OverviewDividend safetyDividendsFundamentals
172.02M
Market cap
–
Current P/E
13.70x
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures.

Similar securities

Based on sector and market capitalization

AcouSort AB
Intervacc AB
Toleranzia AB
Enorama Pharma AB
Neola Medical AB
IRRAS AB (publ)
Report issue